The AMA called for alterations for insurers, including terminating cost-sharing and prior authorization for chronic pain and OUD medications and removing restrictions on Medicaid preferred drug lists.
Managing moderate or severe postoperative pain, which affects 75% of patients in the United States, remains a challenge for physicians.
Vyepti™ (eptinezumab-jjmr; Lundbeck) is now available for the preventive treatment of migraine in adults through select specialty distributors and pharmacies.
Legally dispensed marijuana products have stronger concentrations of THC and CBD than needed for chronic pain relief.
The results provide insights into the underlying causes of relapse and can be used to gain further understanding of the long-term effect of pharmacotherapy for sustained opioid use disorder recovery.
The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.
Professional societies issue stern warning not to inappropriately prescribe or stockpile medications for COVID-19.
Climate change poses a significant threat to global public health by increasing the incidence of novel infectious diseases, as well as the spread of existing ones.
Researchers conducted a cross-sectional, hospital-based study to determine the association between smartphone use and worsening symptoms of migraine, chronic migraine, and tension-type headaches.
Implementation of Florida’s House Bill 21 (HB21) in July 2018 has led to reductions in opioid use and changes in opioid prescribing practices across the state.
Please login or register first to view this content.
